Navigation Links
Pearl Therapeutics Announces Positive Results for Phase 2b Dose-Ranging Study of Formoterol MDI
Date:8/30/2011

bronchodilator product comprised of a long-acting muscarinic antagonist (LAMA) and a long-acting beta-2 agonist (LABA) delivered via a metered dose inhaler (HFA MDI); and PT010, a triple-combination product that combines the LAMA and LABA components of PT003 with an inhaled corticosteroid (ICS) for twice-daily administration from an HFA MDI for the treatment of severe COPD. Both PT003 and PT010 are developed with Pearl's proprietary porous particle cosuspension technology, which allows the formulation of multiple products in the MDI format, with highly stable, robust and aerodynamically efficient drug delivery. Founded in 2006, Pearl Therapeutics is privately held and backed by 5AM Ventures, Clarus Ventures, New Leaf Ventures and Vatera Healthcare. For more information, please visit www.pearltherapeutics.com.

Editor's note: Foradil® is a registered trademark of Astellas Pharma; and Aerolizer® is a registered trademark of Novartis AG.


'/>"/>
SOURCE Pearl Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Pearl Therapeutics Advances Its Long-Acting Bronchodilator Combination Product Candidate into Four Additional Phase 2 Studies
2. Pearl Therapeutics Phase 2b Results Show a 50% Improvement in Lung Function with PT003 Compared to Spiriva® and Foradil® in Patients with COPD
3. Asante Solutions Receives FDA Clearance for Pearl™ Insulin Pump
4. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
5. Pearl Therapeutics to Present Complete PT003 Results from Phase 2b COPD Study in a Late-Breaker Session at the American Thoracic Society Annual Meeting
6. Asante Solutions, Inc. Receives CE Mark for Pearl™ Insulin Pump
7. Prime Therapeutics Drug Trend Insights Reports One of the Lowest Drug Spending Increases in the Industry
8. Precision Therapeutics Named on Inc. 500
9. 5000 2011 List and Recognized for Achievements in Personalized Medicine Industry
10. Cell Therapeutics Submits Day 120 Response for Pixantrone Marketing Authorization Application to European Medicines Agency; Potential Q1 2012 Opinion on Approval
11. Inhibikase Therapeutics Receives FDA Clearance for Phase II Trial of IkT-001 to Treat JC Virus Infection, the Cause of Progressive Multifocal Leukoencephalopathy (PML) in Multiple Sclerosis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... FRANCISCO , May 21, 2013 ... of the American Psychiatric Association show that the ... and clinically meaningful response and remission in patients ... phase of therapy, which were maintained through one ... treatment, 62 percent of patients achieved symptomatic improvement ...
(Date:5/21/2013)... 21 de mayo de 2013 La junta ... filiales incluyen OMNIlife science®, Inc., Enztec, Ltd. y Praxim, ... su junta. Guy Mayer, un ejecutivo ortopédico experimentado, será ... David Johnson , un experto refutado en ... Antes de unirse a OSI como presidente de ...
(Date:5/21/2013)... PRINCETON, N.J. , May 21, 2013 /PRNewswire/ ... consulting company, today announced that 13-year veteran ... Chief Executive Officer. Geraghty,s experience includes more than ... senior management positions with manufacturing organizations. He succeeds ... retiring after serving as Kepner-Tregoe,s Chairman of the ...
Breaking Medicine Technology:New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients with Depression using NeuroStar TMS Therapy System 2New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients with Depression using NeuroStar TMS Therapy System 3New Data Show Long-Term Benefit of Transcranial Magnetic Stimulation in Difficult-to-Treat Patients with Depression using NeuroStar TMS Therapy System 4Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 2Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 3Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 2Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 3
... Inc. (NYSE Amex: PTN ) announced that it ... Investment Conference / 12th Annual Healthcare Conference on Tuesday, September ... place September 12-15 at the New York Palace Hotel in ... and Chief Executive Officer of Palatin Technologies, will provide an ...
... HILL, N.C., Sept. 10 New Product Planning (NPP) ... new product development activities that set the stage for ... importance for NPP groups is medical marketing activities such ... Leading organizations understand that investing in educating the medical ...
Cached Medicine Technology:Best Practices, LLC Research Highlights Critical Role of Medical Marketing in New Product Launch Success 2
(Date:5/21/2013)... Beach, CA (PRWEB) May 21, 2013 ... 3rd Annual EB-5 Investment Summit: Dealmakers Conference in ... Dealmakers Conference will focus on exploring alternative finance ... provide the latest market, legal and economic information, ... immigration and legal professionals within the EB-5 industry. ...
(Date:5/21/2013)... Angeles, CA (PRWEB) May 21, 2013 According ... “Time to Rethink the Use of Botox,” Botox ... world since their approval in 2002 (Go to goo.gl/8iYbD). Although ... become quite popular with men. The injection makes facial wrinkles ... single Botox injection last for about three months. This means ...
(Date:5/21/2013)... Diversity Focus, a non-profit organization striving to improve ... the Creative Corridor region, is releasing results for its ... on Thursday, May 23rd at 10:30 a.m. The ... , The survey is a critical component to ... attract, nurture and retain people of diverse backgrounds, cultures ...
(Date:5/21/2013)... paper recently published in the New England Journal ... at the University of Colorado School of Medicine finds ... can be used to identify individuals at risk for ... fairly common variant of the gene for mucin-5B, a ... by the bronchial tubes. While this variant of the ...
(Date:5/21/2013)... Brazilian funding agency for scientific and technological research So ... So Paulo, announced an investment estimated in US$ 680 ... (RIDCs) for a period of up to eleven years, ... 7. , Funding for the 17 RIDCs will ... faculty, technicians, support personnel, and infrastructure). Host institutions will ...
Breaking Medicine News(10 mins):Health News:Artisan Business Group to Host EB-5 Investment Conference in Long Beach, California 2Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2Health News:Researchers find genetic risk factor for pulmonary fibrosis 2Health News:Research at the cutting edge of knowledge 2
... SATURDAY, June 11 (HealthDay News) -- For most people, insect ... for those who are allergic to them, researchers warn. ... million people have to go to emergency departments after suffering ... American College of Allergy, Asthma and Immunology, which recently released ...
... HealthDay Reporter , FRIDAY, June 10 (HealthDay News) ... sex? That,s the finding from a new study ... of satisfaction in the bedroom. Researchers from Johns Hopkins ... than 3,200 men and women ages 18 to 26, analyzing ...
... News) -- Emotional abuse in childhood can lead to sleep ... analyzing nearly 900 adults ageD 60 and older, researchers found ... earlier were at greater risk for poor sleep quality years ... to exert an influence on our well-being decades later through ...
... 10 (HealthDay News) -- Men may be far less likely than ... they should make the effort, a Loyola University physician says. ... rates for heart disease, cancer, stroke and AIDS. But a U.S. ... to see a doctor on a regular basis. For many ...
... of medicine and director of the rheumatology division ... with colleagues from the medical center for rheumatoid ... and the blogosphere to discuss advances in the ... can be viewed at: , http://coe.musculoskeletaldisease.webdev.nyumc.org/research/whats-up-with-ra-webinar ...
... , THURSDAY, June 9 (HealthDay News) -- The U.S. Food ... a class of drugs used primarily to treat enlarged prostates, ... aggressive form of prostate cancer. In a statement released ... sold under the brand names Proscar and Propecia (sold by ...
Cached Medicine News:Health News:Insect Stings Hold Deadly Risk for Some 2Health News:Self-Confidence, Empathy May Make for Better Sex 2Health News:Self-Confidence, Empathy May Make for Better Sex 3Health News:Emotional Abuse in Childhood May Disrupt Sleep Decades Later 2Health News:Men Urged to Lead by Example and See a Doctor Regularly 2Health News:NYU Langone rheumatologists share insight with online RA community 2Health News:Drugs for Enlarged Prostate May Raise Risk of Aggressive Cancer 2Health News:Drugs for Enlarged Prostate May Raise Risk of Aggressive Cancer 3
... Eyes enzymatic cleaner is a ... removes stubborn deposits in as ... eyes enzymatic cleaner contains an ... irritating film on soft contact ...
... These specialty Eraser instruments have been ... with the right tool for situations ... a series of 25 gauge intraocular, ... discrete treatment of target tissues for ...
Wet-Field Hemostatic Eraser bipolar tip, packsize is 10/box....
Titanium. Straight shafts with curved lower tip. Upper tip fits into positioning hole while lower jaw stabilizes the lens. Flat smooth handle with dull finish. Most popular size or model....
Medicine Products: